deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT00892736

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions BRCA1 Mutation Carrier BRCA2 Mutation Carrier Basal-Like Breast Carcinoma Breast Carcinoma Estrogen Receptor Negative HER2/Neu Negative Hereditary Breast and Ovarian Cancer Syndrome Ovarian Carcinoma Pancreatic Carcinoma Progesterone Receptor Negative Prostate Carcinoma Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Solid Neoplasm Triple-Negative Breast Carcinoma
Interventions Laboratory Biomarker Analysis Pharmacological Study Veliparib
Updated 8 times since 2017 Last updated: Jun 28, 2018 Started: Apr 20, 2009 Primary completion: May 19, 2017 Completion: May 19, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00892736, this PHASE1 trial focuses on BRCA1 Mutation Carrier and BRCA2 Mutation Carrier and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotActive Not Recruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotActive Not Recruiting~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

▶ Show 3 earlier versions

  1. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations